Business Context and Reporting Period
The supplied filing is Brilliant Acquisition Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2022—not a filing identified as T3 Defense Inc. Brilliant was a blank-check company seeking a business combination, with a stated focus on Asia-Pacific businesses. It had not begun operations or generated operating revenue.
On February 22, 2022, Brilliant agreed to merge with Nukkleus Inc. If completed, Nukkleus stockholders were expected to own approximately 66% and Brilliant shareholders approximately 34% of the combined company, assuming no trust-account redemptions. The merger was subject to completion and the filing gives no assurance it would close.
Financial Results and Liquidity
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Operating revenue | None | None |
| Operating costs | $469,271 | $78,411 |
| Net loss | $460,282 | $20,373 |
| Net loss per share | $0.08 | $0.00, rounded |
| Net cash used in operating activities | $699,248 | $85,864 |
| Cash outside trust at period end | $154,255 | $626,953 at March 31, 2021 |
At March 31, 2022, trust-account investments were $41.50 million, total assets were $41.81 million, and current liabilities were $3.06 million. The company reported a $2.76 million working-capital deficit. Current liabilities included $2.26 million in related-party promissory notes and $570,600 due to a related party. Sponsor notes were non-interest bearing and generally payable upon completion of a business combination. The filing reported no long-term debt.
Cash from investing activities was $5.89 million, reflecting $6.53 million released from the trust for shareholder redemptions, offset by a $634,594 trust deposit. Financing activities used $5.32 million, principally due to the redemption payment, partly offset by sponsor funding. The trust balance fell from $47.39 million at December 31, 2021 to $41.50 million at March 31, 2022.
Material Changes and Unusual Items
- Operating costs rose substantially year over year, contributing to a larger quarterly net loss.
- At a March 2022 extension vote, 633,792 shares were redeemed for approximately $6.53 million, or about $10.30 per share. The sponsor deposited a net $634,594 into the trust in connection with the extension.
- The business-combination deadline was extended to July 23, 2022. The filing states that Brilliant had not completed a business combination as of the report date.
- Fair-value remeasurement of private warrant liabilities generated $5,041 of other income in Q1 2022, versus $56,901 in Q1 2021. Interest income was $3,948 versus $1,137.
Outlook, Risks, and Controls
Management planned to pursue the Nukkleus transaction and stated it expected available resources, including potential sponsor or other financing, to support operations through the earlier of a business combination or July 23, 2022. However, no financing source had committed to provide additional capital. Management disclosed substantial doubt about the company’s ability to continue as a going concern; failure to complete a business combination or obtain another extension could require liquidation and redemption of public shares.
The filing cites possible adverse effects from COVID-19 and the Russia-Ukraine conflict, including financing and transaction-market disruption. No specific impacts were quantifiable. No formal financial guidance was provided. The company also disclosed ineffective internal control over financial reporting due to a material weakness in accounting for complex warrant and redeemable-share transactions; remediation efforts were planned, with no assurance of success.
Most Important Facts to Verify
- Confirm the intended issuer: the supplied document names Brilliant Acquisition Corporation, not T3 Defense Inc.
- Verify whether the Nukkleus merger closed, and review final ownership, financing, and redemption outcomes.
- Check the trust balance, sponsor funding, and any deadline extension or liquidation developments after July 23, 2022.
- Review remediation of the disclosed material weakness and subsequent control assessments.
- Reconcile an apparent equity discrepancy: the balance sheet reports total shareholders’ deficit of $915,236, while the statement of changes in equity reports $916,236 at March 31, 2022.